Genetic Association of Glucocorticoid Receptor Gene Polymorphisms With Binge Eating

Obesity Clinical Trial

Official title:

Genetic Association of Glucocorticoid Receptor Gene Polymorphisms With Binge Eating Disorders in Type 2 Diabetic Obese Female Adolescents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04786054
• Other study ID #: BEDCAI37628
• Status: Completed
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: February 1, 2021

Study information

• Verified date: March 2021
• Source: Corporacion Parc Tauli
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the present study was to specifically screen obese diabetic adolescent female individuals for BED, checking the variants of the GR gene (rs56149945; rs41423247) amongst identified individuals, and this led to assessing the impact of binge eating disorders on glycaemic control in obese diabetic adolescent females in Pakistan, South Asia.

Description:

Challenges in eating for diabetic adolescents can be categorized as eating disorders (ED) and disordered eating symptoms (DES). Binge-eating disorder (BED) is defined as recurrent episodes of binge eating at least once a week over a three-month time period and it is accompanied by feeling the lack of control and marked distress over one's eating behaviour. The aim of the present study was to specifically screen obese diabetic adolescent female individuals for BED, checking the variants of the GR gene (rs56149945; rs41423247) amongst identified individuals, and this led to assessing the impact of binge eating disorders on glycaemic control in obese diabetic adolescent females in Pakistan, South Asia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 91
• Est. completion date: February 1, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 10 Years to 19 Years

Eligibility

Inclusion Criteria:

• Unmarried females diagnosed with Type 2 diabetes > 12 months

• Age 10-19 years

• Obesity class I and II (based on BMI range of 30 - 40).

Exclusion Criteria:

• Presence of psychosis, major psychiatric or neurocognitive disorder

• Substance use

• Untreated attention-deficit hyperactivity disorder

• Use of psychopharmacological medications or psychotherapy

• Class III obesity

Related Conditions & MeSH terms

• Adolescent Behavior
• Binge-Eating Disorder
• Bulimia
• Diabetes Mellitus, Type 2
• Diabetes Type 2
• Disease
• Eating Disorders
• Feeding and Eating Disorders
• Obesity

Intervention

Diagnostic Test:
• BED Questionnaire
BED Questionnaire

Locations

Country	Name	City	State
Pakistan	Zainab Khan	Lahore	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BED	Presence of BED detected by individuals who score high on the BEDS7 Questionnaire administered	Baseline
Secondary	NR3C1 Presence of variants of the GR gene (rs56149945; rs41423247)	Presence of variants of the GR gene (rs56149945; rs41423247)	Six months into the study after identifying all individuals who scored high on the BEDS7 Questionnaire